Plain-English translation of NCT05712200 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to prevent blood clots and strokes in people with atrial fibrillation—a heart rhythm problem—who cannot safely take standard blood-thinning pills. The medication is given as a shot under the skin once a month. Half of the participants will receive the medication, and half will receive a placebo (inactive shot) to see if the medication truly works.
People with atrial fibrillation are at high risk for blood clots and strokes, but many cannot take standard blood-thinning medications because of bleeding risks or other health conditions. This trial is testing whether this new treatment can safely protect these patients.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic for a screening period (up to 60 days) to confirm you qualify. Then you will randomly receive either the monthly injection or a placebo shot, and visit the clinic regularly while your health is monitored. The main study continues until at least 111 participants experience a blood clot or stroke event, which helps researchers determine if the medication works. After that, you will have an end-of-study visit, and some participants may be offered the chance to continue receiving the active medication in an optional extension study.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States